Rural 340B Access Act of 2024
Latest Action
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Official Summary
Official summary has not been imported yet.
GovScope Watchdog™
AI Government Intelligence™The Rural 340B Access Act of 2024 is a Senate bill introduced in the 118th Congress aimed at addressing issues related to the 340B Drug Pricing Program in rural areas. The bill's text and official summary are not available, but it was referred to the Senate Committee on Health, Education, Labor, and Pensions. The bill is categorized under the health policy area and is currently marked as failed or expired.
This bill sought to improve access to the 340B Drug Pricing Program for rural healthcare providers but did not advance beyond committee referral and is now expired.
- The bill focuses on the 340B Drug Pricing Program, which allows eligible healthcare providers to purchase outpatient drugs at reduced prices.
- It specifically targets rural access issues within this program, aiming to support rural healthcare providers.
- The bill was introduced in the Senate and referred to the Committee on Health, Education, Labor, and Pensions but did not progress further.
['Rural healthcare providers eligible for the 340B program', 'Patients in rural areas who rely on these providers for affordable medications', 'Potentially, rural hospitals and clinics seeking cost reductions on outpatient drugs']
['Lack of available full bill text and official summary limits understanding of specific provisions and implementation details.', 'Potential challenges in oversight and enforcement of expanded access provisions if included.', 'Possible fiscal impact on federal drug pricing programs and budgets, though specifics are unknown.']
The bill was introduced during the 118th Congress and referred to the Senate Committee on Health, Education, Labor, and Pensions. It did not advance beyond committee referral and is now classified as failed or expired. The 340B program has been subject to ongoing legislative and regulatory discussions concerning eligibility and access, particularly for rural providers.
Hidden impact flags detected: 1
GovScope reviewed 1 policy-risk categories. Hover for a quick definition. Click detected flags for bill-specific details.
['If enacted, the bill could have led to increased availability of discounted drugs in rural areas, potentially improving healthcare outcomes.', "Changes to the 340B program eligibility or access might have affected drug manufacturers' pricing strategies and federal program costs.", 'Enhanced rural provider participation could have influenced healthcare delivery patterns in underserved areas.']
Due to the absence of the full bill text and official summary, transparency is limited, making it difficult to assess the bill's detailed provisions, fiscal impact, and enforcement mechanisms. Monitoring similar future legislation with complete documentation is recommended to ensure informed public and legislative scrutiny.
GovScope Intelligence Roadmap
Future bill intelligence will connect sponsors, committee referrals, related votes, campaign finance, disclosures, and stock trades into one legislative intelligence view.